Progen Industries . Announced today positive preliminary results from a Phase II study of PI-88 for the treatment of patients with primary liver cancer following surgical resection of the tumor. The study showed that PI-88 increased time, results, arecurrence by 76 percent.
The treatment of patients in a post – resection liver cancer setting is a very good match for the biological mechanism of action of PI-88 We know despite the patient’s surgery to remove the tumor are still small tumors. Available. PI-88 works through a process called angiogenesis, or the inhibition of the growth of new blood vessels to these tumors, and also to the spread of tumors or metastases. It is this dual mechanism of action that we believe PI-88 has the potential an exciting an exciting alternative to current cancer therapies.
In the next 40 years, nearly all of the 2.3 billion projected increase will be in the less developed regions, with nearly half in Africa. Continue reading “Progen Industries.”